Key Takeaways
- The global AI in biotechnology market is projected to grow from USD 3.4 billion in 2025 to USD 20 billion by 2034, at a CAGR of 21.6%.
- Major drivers include advancements in personalized medicine, increased automation, and robust governmental support for biotech innovations.
- North America currently leads the market, while the Asia Pacific region is expected to see the fastest growth rate from 2025 to 2034.
Market Overview
The global artificial intelligence (AI) in biotechnology market was valued at approximately USD 3.4 billion in 2025 and is anticipated to reach around USD 20 billion by 2034. This growth reflects a compound annual growth rate (CAGR) of 21.6% from 2025 to 2034, according to a recent study by Statifacts.
Key factors fueling this market expansion include the integration of AI in various biotechnology applications, significant investments, and collaborative initiatives for developing targeted therapies. Organizations are increasingly adopting AI technologies for automating processes, from raw material procurement to product market entry, thus streamlining workflows for both industries and researchers. The growing emphasis on environmental sustainability is also inspiring the development of eco-friendly biotechnological products.
AI technologies, including machine learning, deep learning, and big data analytics, are enhancing processes across the biotechnology landscape, improving diagnostics, drug discovery, and personalized treatment development. The synergy of bioinformatics, gene editing, and 3D bioprinting tools with AI is expected to broaden the scope of applications within the biotechnology sector.
As the demand for personalized medicines increases, there is a notable growth in strategic collaborations among biotechnology firms. This collaborative environment, coupled with government support and accelerated regulatory approvals, is driving innovation. The drug target identification applications segment is highlighted as the largest revenue generator within the market, bolstered by predictive modeling techniques improving patient outcomes in diagnostics and treatment.
Regionally, North America remains the dominant market due to advanced healthcare infrastructure and ample investment in AI technologies. However, the Asia Pacific region is predicted to experience the fastest growth, aided by increasing investments in R&D, favorable regulations, and expanding healthcare infrastructure.
In 2024, collaborative ventures such as Gilead Sciences Inc.’s partnership with Terray Therapeutics exemplify industry trends toward innovative drug discovery. Additionally, funding rounds, like Enveda Biosciences’ $130 million in series C funding, signify robust investment in AI-driven biotech solutions.
Overall, the AI in biotechnology sector is poised for substantial growth, driven by technological advances, industry collaborations, and the need for efficient, personalized healthcare solutions.
The content above is a summary. For more details, see the source article.